FKBP52-Tau Interaction as a Novel Therapeutical Target for Treating the Neurological Disorders Involving Tau Dysfunction

Abstract

The invention relates generally to neuroprotection and repair in neurological disorders involving Tan dysfunction (including Alzheimer's disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 mid Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tan polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.

1 - 10 . (canceled) 
     
     
         11 . A method of preventing or treating neurological disorders involving Tau dysfunction, in a subject thought to have or be predisposed to having a neurological disorder involving Tau dysfunction, comprising the administration to said subject of an effective amount of a compound which modulates the interaction between the Tau and the FKBP52 protein. 
     
     
         12 . The method according to  claim 11 , wherein the neurological disorders involving Tau dysfunction are selected among Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration and frontotemporal lobar degeneration. 
     
     
         13 . The method according to  claim 11 , wherein said compound is combined with pharmaceutically acceptable excipients.